INVESTOR ALERT: Kessler Topaz Meltzer & Check, LLP Announces that Investors with Substantial Losses in Shares of Actinium Pharmaceuticals, Inc. Have Opportunity to Lead Class Action Lawsuit
ATNM Investor Alert: Bronstein, Gewirtz & Grossman LLC Announces Investigation of Actinium Pharmaceuticals Inc.
NEW YORK, March 25, 2023 -- Bronstein, Gewirtz & Grossman LLC is investigating potential claims against Actinium Pharmaceuticals Inc. ("ATNM" or the "Company") (NYSE: ATNM) on behalf of investors who acquired the Company's securities during the period from March 2020 to the present.
The investigation is focused on whether the Company and its officers and/or directors have made false or misleading statements, breached their fiduciary duties, or violated certain federal securities laws.
On March 23, 2023, the Company issued a press release announcing that it had received a "Notice of Allowance" from the United States Patent and Trademark Office ("USPTO") for a key patent related to its ARC-APL-1 investigational new drug candidate. However, the Company's stock price declined significantly following the announcement, prompting concerns that the patent may not be as valuable as previously suggested.
The investigation is ongoing and any investor who acquired ATNM securities during the period from March 2020 to the present and suffered losses as a result of the Company's alleged misconduct is encouraged to contact the firm. The investigation focuses on potential claims related to the Company's patent portfolio, its investigational new drug candidates, and its financial statements.
If you are a current or former shareholder of ATNM and have significant financial losses, you have the option to join this investigation by providing your information to the firm. The investigation is ongoing, and the firm is working to determine whether the Company and its officers and/or directors have engaged in any wrongdoing that may have impacted the value of the Company's securities.
Contact information for the firm is as follows:
Bronstein, Gewirtz & Grossman LLC 212-697-6484 info@bg-g.com